News | August 06, 2024
OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously
Revolutionary technology will further boost OneSource’s scientific services offerings
Revolutionary technology will further boost OneSource’s scientific services offerings
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
Cipla completes transfer of Generics Business Undertaking
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
The companies will spread the adoption of the latest HOS and Mass Spec technologies to help scientists improve the safety, stability, and effectiveness of biotherapeutics
Approval to dramatically change CAR-T therapies landscape
Subscribe To Our Newsletter & Stay Updated
